India's drug regulator has approved Takeda's QDENGA, marking the first dengue vaccine authorized in the country, Bloomberg News reported on Monday.
The approval comes as dengue cases in India have surged 11-fold over the past two decades, addressing a critical public health need, the news wire said.
Takeda is partnering with Biological E to expand manufacturing, aiming to produce 50 million doses annually in India as part of the company's global target of 100 million doses per year by 2030, the publication said.
Takeda did not immediately respond to' request for comment.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)